You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
SYMPLICITY™ BLOOD PRESSURE PROCEDURE
The Medtronic Symplicity blood pressure procedure helps manage high blood pressure (hypertension),*1–3 which is shown to lower your risk of heart attacks, strokes, and other serious health problems.4
Reducing blood pressure by 10 mmHg can lower your risk of:
heart failure4
↓28%
cardiovascular events4
↓20%
stroke4
↓27%
While it may not affect how many medications you take, the Symplicity blood pressure procedure helps manage high blood pressure without adding another pill to your daily regimen.1,2
The Symplicity blood pressure procedure is proven to safely help manage blood pressure in people who are taking blood pressure medication and those who are not.1,2
-16.7
mmHg
blood pressure management in a three-year study of people who received the Symplicity procedure3
The Medtronic Symplicity blood pressure procedure, just like any medical procedure, has risks. It's important to talk with your doctor about the benefits and risks.
The potential risks as well as complication rates for the Symplicity blood pressure procedure are similar to those associated with other interventional procedures.
Get more details about the Symplicity blood pressure procedure.
Includes Symplicity Spyral™
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. June 9, 2018;391(10137):2346–2355.
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. May 2, 2020;395(10234):1444–1451.
Mahfoud F, Mancia G, Schmieder R, et al. Blood pressure and MACE reductions after renal denervation: 3-year Global Symplicity Registry results. Presented at PCR e-course 2022.
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis. Lancet. March 5, 2016;387(10022):957–967.